Humana stock surged 11.6% to close at $431.87 on Friday, October 9, 2026, after the insurer said 95% of its Medicare Advantage members will be in plans rated four stars or higher in the 2027 Star RatiHumana stock surged 11.6% to close at $431.87 on Friday, October 9, 2026, after the insurer said 95% of its Medicare Advantage members will be in plans rated four stars or higher in the 2027 Star Rati
Why Is Humana Stock Surging? Medicare Star Ratings Shake Up HUM, ALHC and CVS
Humana stock surged 11.6% to close at $431.87 on Friday, October 9, 2026, after the insurer said 95% of its Medicare Advantage members will be in plans rated four stars or higher in the 2027 Star Ratings, up from about 20% a year earlier. The same ratings, released by the Centers for Medicare & Medicaid Services (CMS) on October 8, sent Alignment Healthcare down 13.4% after its main California plan slipped below four stars.
Key Takeaways
- Humana (NYSE: HUM) rose 11.6% to $431.87 after reporting that 95% of its Medicare Advantage members are in plans rated 4 stars or higher for 2027.
- J.P. Morgan had expected Humana's 4-star share to land between 60% and 70%.
- Alignment Healthcare (NASDAQ: ALHC) fell 13.4% to $7.55 after its largest contract, covering about 75% of its health plan members, dropped to 3.5 stars.
- Ratings tightened across the industry: 37% of Medicare Advantage drug plans earned 4 stars or more for 2027, down from 44%, and CVS Health slipped 1.9%.
- The 2027 Star Ratings set bonus payments for 2028, so the revenue impact arrives in 2028, not next year.
Why Did Humana Stock Jump on October 9?
Humana stock jumped because its 2027 Star Ratings came in far better than investors expected, reversing a two-year ratings slump that had cut into its government bonus payments. Humana said 95% of its Medicare Advantage members are in plans rated 4 stars or higher, against roughly 20% in last year's ratings.
The details, from Humana's announcement:
- 4.5-star plans: 42% of Medicare Advantage members.
- Contracts: six contracts rated 4.5 stars and twelve rated 4.0 stars, eleven more at 4 stars or above than a year earlier.
- Drug plan: its stand-alone Part D contract earned 4.5 stars.
- Guidance: Humana reaffirmed its 2026 adjusted earnings guidance of at least $9 per share and said it expects a 2028 benefit to be used for one-time investments and returns to shareholders.
"We're extremely proud of these Star Ratings," CEO Jim Rechtin said. The result beat Wall Street's bar by a wide margin. J.P. Morgan had modeled a 60% to 70% four-star share, Reuters reported, and Evercore ISI analyst Elizabeth Anderson said the improvement "reflects the importance management has placed on fixing this metric over the past year."
What Are Medicare Star Ratings and Why Do They Move Insurer Stocks?
Medicare Star Ratings are CMS's one-to-five-star quality scores for Medicare Advantage and drug plans. Plans rated 4 stars or higher qualify for quality bonus payments, a 5% increase to the benchmark used to set what Medicare pays them, and they keep a larger share of savings as rebates for extra member benefits.
Two features make the ratings a stock-moving event:
- The money is large: crossing the 4-star line can add or remove billions of dollars of revenue for a big insurer.
- The timing is delayed: ratings published in October 2026 are the 2027 Star Ratings, and they determine bonus payments in 2028.
TD Cowen analyst Ryan Langston estimates Humana's improved ratings could add $3 billion or more in 2028 revenue, according to Healthcare Dive. How much of that reaches profit depends on how much Humana reinvests in member benefits.
How Did Humana Recover From Its Ratings Collapse?
Humana recovered by fixing the contract that had dragged its ratings down. In the 2025 ratings, its share of members in 4-star plans fell to 25% from 94%, after its largest contract dropped from 4.5 to 3.5 stars. Its 2026 ratings stayed weak at about 20%, and the insurer lost a lawsuit challenging the 2025 calculations.
Humana told investors last year it expected "meaningfully higher" results in the 2027 ratings. Its largest contract is now back above the 4-star threshold. Humana pointed to operating gains behind the result, including 534,000 more members completing an annual preventive visit and 663,000 additional care opportunities met compared with the prior year.
J.P. Morgan analyst Lisa Gill called it "a clear win for a company that has been working toward this outcome for several years."
Why Did Alignment Healthcare Stock Fall?
Alignment Healthcare stock fell because its biggest contract lost its 4-star rating. Its California HMO contract, H3815, which serves about 75% of its health plan members, is expected to receive 3.5 stars for 2027, down from 4.0, according to the company's October 8 filing.
ALHC dropped about 20% in premarket trading and closed down 13.4% at $7.55. What the company and analysts have said so far:
- Timing of the hit: Alignment expects no revenue impact in 2026 or 2027; the loss falls on 2028 quality bonus payments, partly offset by risk-sharing with its providers.
- Size of the hit: TD Cowen's Langston estimates more than $170 million of lost 2028 revenue. Alignment has not given its own figure.
- Response: the company plans administrative appeals and expects to start litigation over certain CMS measures and methods.
- Analyst moves: J.P. Morgan cut its price target to $10 from $22 and KeyBanc to $12 from $28, both keeping Overweight ratings, while William Blair downgraded the stock to Market Perform.
Its six other eligible contracts kept 4 stars or higher, with three at 4.5 stars.
How Did CVS and UnitedHealth Fare in the 2027 Star Ratings?
CVS Health and UnitedHealth both saw fewer members in 4-star plans, as the 2027 ratings got tougher across the industry. J.P. Morgan estimates UnitedHealth's 4-star share will fall to about 67% from 81%, and CVS's to roughly 70% from 84%. CVS shares closed down 1.9% at $86.16 on Friday.
Industry-wide figures from Healthcare Dive show how much the bar rose:
- 4-star plans: 37% of Medicare Advantage plans with drug coverage earned 4 stars or more for 2027, down from 44%.
- 5-star contracts: 15, down from 22.
- Average rating: 3.99, down from 4.01.
That makes Humana's jump stand out further. It moved from the sector's biggest ratings casualty to its clearest winner in a year when most large rivals lost ground.
What Should Investors Watch Next?
Investors should watch how insurers use their bonus money, how Medicare enrollment plays out, and whether the ratings hold up under appeal.
- Medicare open enrollment, October 15 to December 7: higher-rated plans can offer richer benefits, which can shift members toward Humana.
- Humana's 2028 benefit: the company has said it will disclose the size of the benefit and how it splits between one-time investments and shareholder returns once it has more 2028 information.
- Appeals and lawsuits: Alignment's challenge, and any others, could change individual contract ratings.
- 2028 payment rules: CMS's rate notices for 2028 will set the base that bonus payments are added to.
How Can You Buy Humana Stock on MEXC?
Eligible investors can buy real Humana (HUM) shares through MEXC RealStocks, where shares are held through a licensed partner broker. RealStocks follows regular U.S. market hours, is quoted in USD and can be funded with USDT. You can follow the price on MEXC's HUM stock page.
To start, open a RealStocks account on MEXC and complete the broker's identity verification. Friday's moves in HUM and ALHC show how sharply insurer stocks can reprice on a single regulatory release, in either direction.
Frequently Asked Questions
Why did Humana stock go up on October 9, 2026?
Humana rose 11.6% to $431.87 after saying 95% of its Medicare Advantage members are in plans rated 4 stars or higher for 2027, up from about 20% in last year's ratings.
What are Medicare Advantage Star Ratings?
They are CMS's one-to-five-star quality scores for Medicare Advantage and drug plans. Plans rated 4 stars or higher earn quality bonus payments and larger rebates.
When do the 2027 Star Ratings affect Humana's revenue?
The 2027 Star Ratings set bonus payments for 2028, so the revenue impact begins in 2028.
How much could the ratings add to Humana's revenue?
TD Cowen analyst Ryan Langston estimates $3 billion or more in additional 2028 revenue. Humana has not disclosed its own estimate.
Why did Alignment Healthcare stock drop?
Its California HMO contract, which covers about 75% of its health plan members, fell to 3.5 stars from 4.0 for 2027, which will reduce 2028 bonus payments.
Did Humana change its earnings guidance?
Humana reaffirmed its 2026 adjusted earnings guidance of at least $9 per share.
Can I buy Humana stock on MEXC?
Eligible users can buy real HUM shares through MEXC RealStocks. Availability depends on region.
Related Readings
Market Opportunity
4 Price(4)
$0.01686
$0.01686$0.01686
USD
4 (4) Live Price Chart
The articles shared on this page are sourced from public platforms and are provided for reference only. They do not represent the position or views of MEXC. All rights belong to James Mitchell. If you believe any content infringes upon the rights of a third party, please contact service@support.mexc.com for prompt removal. MEXC does not guarantee the accuracy, completeness, or timeliness of any content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be interpreted as a recommendation or endorsement by MEXC. For expert insights and in-depth analysis, visit MEXC Learn.
Latest Updates on 4
View More
Why 98.9% of Zcash Voters Kept Bitcoin-Style Halvings
Zcash holders have overwhelmingly voted to preserve the network’s Bitcoin-style halving schedule as part of the upcoming NU7 upgrade. Nearly 2.4 million ZEC participated in the privacy-preserving vote, representing roughly two-thirds of the approximately 3.6 million ZEC eligible at the snapshot. Of the participating ZEC, 98.9% supported keeping scheduled halvings rather than replacing them with a smoother issuance model, while 99.9% backed reducing block time from 75 seconds to 25 seconds
2026/09/18
Robinhood Stock Tokens Hit $10.4B: Is DeFi Repricing Equities?
Robinhood Stock Tokens have generated approximately $10.4 billion in spot DEX trading volume over the past 30 days, highlighting how quickly tokenized equity exposure is moving from brokerage-style access into crypto-native market infrastructure. The figure measures trading turnover rather than capital invested, TVL or underlying equity ownership, but its scale is still notable because activity is increasingly taking place through decentralized exchanges rather than exclusively inside a closed brokerage interface
2026/09/24
Tokenized Stock Trading Hits $20.9B: Why Uniswap Leads
Tokenized stock trading has reached a new liquidity milestone, generating approximately $20.9 billion in decentralized exchange volume over the past 30 days. Uniswap accounted for 60.1% of that activity, with Uniswap v4 representing 40.7% and v3 another 19.4%, equivalent to roughly $12.6 billion in combined trading volume. The figures show that tokenized equities are progressing beyond issuance and brokerage access toward an increasingly active onchain secondary market.
2026/09/28
You May Also Like
HOT
Currently trending cryptocurrencies that are gaining significant market attention
Crypto Prices
The cryptocurrencies with the highest trading volume
Newly Added
Recently listed cryptocurrencies that are available for trading